IP Library Granted Patent US 9,301,929
Granted Patent B2
US 9,301,929 · App. 13/505,819 · Granted Apr 5, 2016

Substituted biaryl derivatives and methods of use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,301,929
App. No.
13/505,819
Granted
Apr 5, 2016
Kind
B2
Abstract

The present invention relates to Substituted Biaryl Derivatives, compositions comprising a Substituted Biaryl Derivative, and methods of using the Substituted Biaryl Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR119 in a patient.

Claims (16)

1. A compound having the formula:

or a pharmaceutically acceptable salt thereof, wherein E is:

each occurrence of R 6 is a ring carbon atom substituent and is independently selected from halo, —CF 3 , —OH, alkyl, C 3 -C 7 cycloalkyl and —O—alkyl;

R 15 is alkyl; and

m is 0 or 1.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each occurrence of R 6 is halo.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 1.

4. The compound of claim 1 , which is

5. A compound which is

or a pharmaceutically acceptable salt thereof.

6. A composition comprising one or more compounds of claim 1 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

7. The composition of claim 6 , further comprising one or more additional therapeutic agents, wherein the additional therapeutic agent(s) are selected from an antidiabetic agent and an antiobesity agent.

8. A method for treating diabetes in a patient, the method comprising administering to the patient an effective amount of one or more compounds of claim 1 , or a pharmaceutically acceptable salt thereof.

9. The method of claim 8 , further comprising administering to the patient one or more additional therapeutic agents, wherein the additional therapeutic agent(s) are selected from an antidiabetic agent and an antiobesity agent.

10. A compound having the structure:

or a pharmaceutically acceptable salt thereof.

Assignments (3)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
CHANGE OF NAME Recorded Mar 27, 2013
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 030102/0196 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2012
From: BOYLE, CRAIG D.; LANKIN, CLAIRE M.; GREENLEE, WILLIAM J.; HARRIS, JOEL M.
To: SCHERING CORPORATION
Reel/Frame 028776/0775 →